Ariana Pelosci
Ariana Pelosci is a managing editor at CancerNetwork and the journal ONCOLOGY, where she covers new cancer therapies, clinical trial outcomes, and patient-centered research across a wide range of malignancies. Her through-line is practice-facing news that connects regulatory decisions and emerging data with real-world treatment, survivorship, and quality-of-life concerns. She works across web and print and also oversees social media, which keeps her coverage tuned to how clinicians and patients engage with oncology content day to day.
Regulatory decisions and new oncology drugs
Pelosci’s core reporting focus is the drug-development pipeline, with a steady stream of pieces on approvals, priority reviews, fast track and breakthrough therapy designations. She reports on targeted and biomarker-driven agents such as capmatinib for MET exon 14 skipping metastatic non–small cell lung cancer, erdafitinib in metastatic urothelial carcinoma, and adagrasib for KRAS G12C–mutated non–small cell lung cancer, emphasizing who benefits and on what evidence. She follows breast cancer closely through stories on agents like enobosarm for androgen receptor–positive, estrogen receptor–positive, HER2-negative metastatic disease and trastuzumab deruxtecan in HER2-low metastatic breast cancer. Her coverage extends into hematologic malignancies and rare diseases, with pieces on bexmarilimab’s orphan drug designation in acute myeloid leukemia and elranatamab’s accelerated approval in relapsed or refractory multiple myeloma. She regularly notes when luspatercept, bemcentinib, and other agents move forward via FDA or European Commission decisions, framing these moves against data from trials such as COMMANDS, KRYSTAL-1, and other pivotal studies.
Clinical trial outcomes and practice impact
Beyond the regulatory headline, Pelosci spends much of her time unpacking clinical trial results and their practical meaning for oncologists.
She writes on survival and disease-control endpoints, including overall and progression-free survival improvements with regimens like nivolumab plus chemotherapy in advanced gastrointestinal cancers, gemcitabine plus cisplatin in nasopharyngeal carcinoma, and belzutifan versus everolimus in renal cell carcinoma. She covers disease-free survival in solid tumors, reporting on pembrolizumab’s impact in non–small cell lung cancer and tamoxifen plus extended letrozole in postmenopausal breast cancer.
Her hematology and cellular-therapy pieces follow trials such as ZUMA-2, EPCORE NHL-1, and ATHENA-MONO, focusing on durable responses in mantle cell lymphoma, large B-cell lymphoma, and maintenance rucaparib in advanced ovarian cancer. She also highlights feasibility and treatment-intensity questions, such as the NEOpredict trial of nivolumab with or without relatlimab in resectable non–small cell lung cancer and tisa-cel’s efficacy versus standard of care in relapsed or refractory follicular lymphoma.
Pelosci often brings in prognostic tools and biomarkers when discussing outcomes. Her reporting includes work on DNA sequencing of bone marrow to detect minimal residual disease and predict relapse in acute lymphoblastic leukemia, contrasting its performance with flow cytometry.
She covers ctDNA reductions associated with improved clinical outcomes in non–small cell lung cancer treated with immune checkpoint inhibitors, as well as lymph node classification approaches that sharpen prognostication in esophageal cancer. Pieces on integrated clinical radiomics models and 18F-FDG PET/CT signatures for breast cancer progression-free survival show a willingness to dig into imaging and data-science methods alongside traditional endpoints.
Across these reports she keeps the tone concise and clinical, centered on what changes for patient care when trials read out and tools perform.
Survivorship, quality of life, and disparities
A distinct strand in Pelosci’s work is survivorship and quality of life, where she tracks how treatment choices and supportive care affect daily living. Her reporting on primary survivorship care in patients with breast cancer and other malignancies considers whether care can move from specialty settings to primary care while remaining feasible and safe.
She covers high-intensity interval training in localized prostate cancer and exercise oncology in metastatic renal cell carcinoma, focusing on improvements in cardiorespiratory fitness, quality of life, and even biomarker shifts such as prostate-specific antigen levels. Radiotherapy de-escalation in human papillomavirus–associated oropharyngeal carcinoma is another recurring theme, where she highlights favorable outcomes alongside better quality of life when radiation doses are reduced.
Pelosci also reports on psychosocial and nutritional dimensions of cancer care. She writes about Latina breast cancer survivors being less likely than non-Latina women to seek psychosocial services, underlining gaps in support even when survivorship care exists. Coverage of malnutrition and its association with post-operative outcomes in gynecologic cancer brings a surgical and nutritional lens to risk and recovery.
Her pieces on disparities in suicide risk following cancer diagnosis and Medicaid’s association with reduced racial and ethnic disparities in de novo stage IV breast cancer situate epidemiologic findings within broader discussions of equity. In work on GLP-1 agonists as a potential weight-loss option for patients with breast cancer, she explores how metabolic therapies intersect with oncology, tying disease trajectory to broader health and survivorship issues.
Broad tumor coverage and multichannel formats
Pelosci’s beat spans solid and hematologic malignancies, and her archive reflects an ability to move between tumor types without losing clinical specificity. She writes on lung cancers, including non–small cell and small cell, renal cell carcinoma, gastric and gastroesophageal junction tumors, esophageal cancers, nasopharyngeal carcinoma, neuroendocrine tumors, and prostate and bladder cancers.
Hematologic coverage ranges from Hodgkin lymphoma and mantle cell lymphoma to multiple myeloma, acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, and large B-cell lymphoma. She periodically addresses cross-cutting topics such as the limitations of real-world studies for informing clinical and reimbursement decisions in novel cancer drugs and themes in symptom management for head and neck cancer.
Her formats are primarily news and trial reports, but she also contributes to podcast-related content, as seen in work tied to Between the Lines™ on mobocertinib use in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer. Alongside her writing, she manages the social media accounts for CancerNetwork and ONCOLOGY, a role that keeps her close to how clinical audiences respond to and share oncology news across platforms.
Across roles and tumor types, Pelosci’s work is consistent in its focus on data, approvals, and patient impact rather than opinion, making her coverage a reliable barometer of where cancer treatment and survivorship research are moving.
4 more health journalists.
Aislinn Antrim
Aislinn Antrim is an associate editorial director at Pharmacy Times and a journalist who connects clinical advances, regulation, and the changing role of pharmacists. She writes pharmacy-centered health coverage on chronic disease therapeutics, specialty and oncology care, workforce pressures, and advocacy. Her reporting explains FDA actions, policy shifts, drug pipelines, and the real-world effects of new evidence on patient care and pharmacy practice. She often uses interviews and expert conversations to show how pharmacists improve adherence, manage side effects, navigate access and benefits, and coordinate care with prescribers. She also covers burnout, staffing strain, and the future of pharmacy practice, with an eye on how policy and economics shape work at the dispenser.
Alex Cabrero
Alex Cabrero is an Emmy award-winning KSL TV reporter who covers where health, safety and community life meet, always focused on how decisions and events affect everyday people. He has been with KSL since 2004, bringing long experience in breaking news, public service coverage and human-centered features. His beat includes public health, emergency response, technology, local infrastructure, environment and science, framed through community well-being and resilience. He reports on issues like mental health initiatives, law enforcement staffing, environmental hazards, rescues, wildfire detection tools, land-use fights and scientific discoveries, making technical and policy details clear for a general audience. He also produces many positive, everyday-life features on families, veterans, farmers, sports and local traditions. His style is direct and conversational, often built around a central person or family whose experience carries the story across TV, digital and social platforms.
Alexandra Frost
Alexandra Frost is a freelance journalist and content marketing writer who turns expert-backed health and family guidance into clear, practical service stories. She covers consumer health, wellness, nutrition, preventive care, medical research, parenting, kids’ mental health, education, products, and lifestyle. Her reporting explains concerns such as inflammation, urinary symptoms, fiber, lung cancer screening, pain treatment, mobility, family dynamics, children’s technology use, and school readiness. She profiles clinicians and scientists, connects research to everyday decisions, and focuses on what readers should watch for, ask, or change. Frost currently writes across multiple outlets, including Good Housekeeping, Cincinnati Magazine, Wirecutter, Popular Science, Success, Healthline, Parents, Women’s Health, Reader’s Digest, Today’s Parent, the Atlantic, the Washington Post, TIME, Consumer Reports, Business Insider, and National Geographic. She also works as a freelance editor, media consultant, and content strategist.
Alexandra Pattillo
Alexandra Pattillo is a freelance journalist who pairs rigorous health and science reporting with intimate accounts of patients’ lives. She covers health, science and wellness for the BBC and other major outlets, including National Geographic, The New York Times, The Atlantic, The Guardian, Outside, CNN and Inverse. Her beat includes eating disorders, women’s health, perinatal mental health, brain health, youth sports, concussion, long-term Covid symptoms, attention, habits and behavioral science. She reports on emerging treatments such as psychedelic-assisted therapy for anorexia, testing evidence, safety and relapse risk. She explains complex research in plain language and examines how it shapes everyday choices. Her reporting uses in-depth interviews with patients, families, clinicians, researchers and coaches. Through the BBC’s Health Gap column, she also covers stigma, unequal access to care and gaps between lived experience and standard medical pathways.